Arena Pharmaceuticals (ARNA) Receiving Somewhat Favorable Media Coverage, Analysis Shows
Press coverage about Arena Pharmaceuticals (NASDAQ:ARNA) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arena Pharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0711753994151 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- ETFs with exposure to Arena Pharmaceuticals, Inc. : September 12, 2017 (finance.yahoo.com)
- Cramer's lightning round: Allergan's in a torturous situa… (finance.yahoo.com)
- Healthcare Stock on Buy Line: Arena Pharmaceuticals, Inc. (ARNA) – Street Observer (press release) (streetobserver.com)
- Borders-Opener Blair Calls For Immigration Controls to Stop Brexit (famososartistas.com)
- Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 (finance.yahoo.com)
Several equities research analysts have recently weighed in on ARNA shares. Citigroup Inc. started coverage on Arena Pharmaceuticals in a report on Tuesday, June 27th. They issued a “buy” rating and a $23.00 price target on the stock. Zacks Investment Research upgraded Arena Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Tuesday, July 4th. BidaskClub upgraded Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, July 7th. ValuEngine upgraded Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Arena Pharmaceuticals in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. Arena Pharmaceuticals has an average rating of “Buy” and an average price target of $36.00.
Shares of Arena Pharmaceuticals (ARNA) opened at 24.30 on Tuesday. The stock has a 50 day moving average price of $22.49 and a 200 day moving average price of $16.97. The stock’s market capitalization is $953.05 million. Arena Pharmaceuticals has a one year low of $11.30 and a one year high of $27.86.
Arena Pharmaceuticals (NASDAQ:ARNA) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.03. Arena Pharmaceuticals had a negative net margin of 16.27% and a negative return on equity of 49.87%. The business had revenue of $6.49 million during the quarter, compared to analyst estimates of $5.58 million. During the same quarter in the prior year, the company posted ($1.10) earnings per share. The company’s revenue was down 31.8% on a year-over-year basis. Equities analysts forecast that Arena Pharmaceuticals will post ($2.94) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Arena Pharmaceuticals (ARNA) Receiving Somewhat Favorable Media Coverage, Analysis Shows” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/arena-pharmaceuticals-arna-receiving-somewhat-favorable-media-coverage-analysis-shows/1555699.html.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Ratings for Arena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.